NasdaqGS:BRKRLife Sciences
Assessing Bruker (BRKR) Valuation After The CellScape XR Spatial Proteomics Launch
Bruker (BRKR) has drawn fresh attention after launching CellScape XR, a next generation spatial proteomics platform designed to support more reproducible, high throughput translational and clinical research in diagnostic and prognostic assay development.
See our latest analysis for Bruker.
Despite the CellScape XR launch and the recent closure of a US$251.37m shelf registration tied to an ESOP offering, Bruker’s 30 day share price return of 12.71% and year to date decline of 23.92% suggest...